Rockville’s RegenxBio Inc. (NASDAQ: RGNX) has more work to do before its eye disease treatment candidate can reach patients — but it’s already seeing some promise.
The company’s ongoing phase 1 and phase 2a trial for the gene therapy program, RGX-314, found the majority of patients with wet age-related macular degeneration required fewer anti-VEGF injections — the current standard of care — to manage the condition, and experienced improvement in vision and retinal thickness when they received its treatment. The one-time treatment has also been well-tolerated with no serious adverse reactions to it, according to the results.
Specifically, 75% of patients in one of the study’s cohorts no longer needed injections, often administered chronically to maintain the disease, after six months. And half of those in another cohort haven’t needed them within a year and a half of starting to receive the RGX-314 therapy.
Patients with wet AMD experience vision loss because new blood…Read the full story from the Washington Business Journal.